Africa Launches Groundbreaking Twice-Yearly HIV Prevention Injection with 99.9% Effectiveness
Africa has reached a historic milestone in HIV prevention as three countries begin rolling out lenacapavir, a revolutionary injection that needs to be taken just twice a year and has shown over 99.9% effectiveness in preventing HIV transmission. According to report, South Africa, Eswatini, and Zambia are leading the continent’s first public distribution of the breakthrough drug, bringing hope to a region that carries the world’s heaviest HIV burden. Lenacapavir works almost like a vaccine in its ability to prevent HIV infection. Unlike daily pills, this injectable treatment only requires administration every six months, making it far more practical for widespread use. The rollout in South Africa is being led by a Wits University research team with backing from Unitaid, a United Nations health initiative. This is particularly significant in a country where roughly one in five adults lives with HIV. “The first individuals have begun using lenacapavir for HIV prevention in South Africa, making it among the first real-world uses of the 6-monthly injectable in low- and middle-income countries,” Unitaid announced, though they didn’t specify exact numbers of people who’ve received the initial doses. Currently, lenacapavir costs about $28,000 (over ₦30 million) per person annually in the United States, a price that puts it far out of reach for most people in affected countries. However, pharmaceutical giant Gilead Sciences has pledged to provide the drug at no profit to two million people in high-burden countries over the next three years. Zambia and Eswatini each received around 1,000 doses last month through U.S. support and launched the program during World AIDS Day events. The real breakthrough is expected by 2027, when affordable generic versions are projected to hit the market at approximately $40 per year in over 100 countries. These generics will be made possible through agreements involving Unitaid, the Gates Foundation, and Indian drug manufacturers. Eastern and southern Africa account for about 52% of the world’s 40.8 million people living with HIV, according to 2024 UNAIDS data.









